Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001318

Drug Information
NameBortezomib
SynonymsCID387447; LDP-341; MolPort-003-845-298; Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; NCI60_029010; PROSCRIPT BORONIC ACID; CHEBI:287372; D03150; CHEBI:41143; CHEMBL325041; Bortezomib (JAN/USAN/INN); Boronic acid, [1-[[1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl) amino]propyl]amino]-3-methylbutyl]-, L-(S)-; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; DPBA; PS-341; Bortezomib; LPD-341; 179324-69-7; SBB071337; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; DB07475; I14-3268; Velcade (TN); LPD 341; NSC681239; S1013_Selleck; NSC-681239; Pyz-Phe-boroLeu; Velcade, MG-341, PS-341, Bortezomib; FT-0082488; AC1L8TUW
Trade NameVELCADE
CompanyTakeda
IndicationFollicular NHL and MCL
[ICD9: 200, 200.4, 202   ICD10: C82-C85, C85.7]
Phase III    [1]
Multiple myeloma
[ICD9: 203.0   ICD10: C90.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7
-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1
-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N
Canonical SMILESB(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O    
Isomeric SMILESB([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 179324-69-7
FormulaC19H25BN4O4
PubChem Compound IDCID 387447.
PubChem Substance IDSID 518755.
ChEBI52717;
SuperDrug ATC IDL01XX32
SuperDrug CAS ID179324697;
Target26S proteasomeInhibitor[2][3][4]
26S proteasomeInhibitor[2]
Ref 1New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. To Reference
Ref 2Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm. 2008 Jul 1;65(13):1221-31. To Reference
Ref 3Takeda. Product Development Pipeline. July 31 2009. To Reference
Ref 4Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade((R))) in chemotherapy-na?¡¥ve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer. 2009 Jun 11. [Epub ahead of print] To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543